REGN (NASDAQ) - Regeneron Pharmaceuticals Inc

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75886F1075
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Web URL: https://www.regeneron.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for REGN (NASDAQ) - Regeneron Pharmaceuticals Inc

Classification

Market Cap in USD 90,838m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1991-04-02

Ratings

Fundamental 7.15
Dividend -
Performance 5y 6.51
Rel. Performance vs Sector 0.39
Analysts 3.92
Fair Price Total Ret. 835.03
Fair Price DCF todo

Technical

Growth TTM 18.96%
CAGR 5y 15.89%
CAGR / Mean Drawdown 5y 1.26
Sharpe Ratio TTM 0.53
Alpha vs SP500 TTM 7.70
Beta vs SP500 5y weekly 0.57
CAPM 6.60%
Average Daily Range 2m 1.63%
Reversal Oscillator 39.48
Volatility GJR Garch 1y 27.14%
Price / SMA 50 2.33%
Price / SMA 200 7.19%
Current Volume 405.5k
Average Volume 20d 403.9k

Dividends

Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%